

# Rosa Jahangiri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4126613/publications.pdf>

Version: 2024-02-01

7  
papers

70  
citations

1937685

4  
h-index

1872680

6  
g-index

7  
all docs

7  
docs citations

7  
times ranked

76  
citing authors

#	ARTICLE	IF	CITATIONS
1	Altered DNA methyltransferases promoter methylation and mRNA expression are associated with tamoxifen response in breast tumors. <i>Journal of Cellular Physiology</i> , 2018, 233, 7305-7319.	4.1	26
2	Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients. <i>Gene</i> , 2019, 685, 24-31.	2.2	18
3	Increased Expression of Gankyrin and Stemness Factor Oct-4 are Associated with Unfavorable Clinical Outcomes and Poor Benefit of Tamoxifen in Breast Carcinoma Patients. <i>Pathology and Oncology Research</i> , 2020, 26, 1921-1934.	1.9	11
4	PAX2 expression is correlated with better survival in tamoxifen-treated breast carcinoma patients. <i>Tissue and Cell</i> , 2018, 52, 135-142.	2.2	9
5	<i>PAX2</i> promoter methylation and <i>AIB1</i> overexpression promote tamoxifen resistance in breast carcinoma patients. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 310-325.	0.9	4
6	Role of and in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer. <i>Molecular Biology Research Communications</i> , 2021, 10, 109-119.	0.3	2
7	Increased Expression of DNA Methyltransferase 1 and 3B Correlates with Tumor Grade in Laryngeal Squamous Cell Carcinoma. <i>Pharmaceutical Sciences</i> , 2020, 27, 393-398.	0.2	0